Therapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management.

IF 2.5 4区 生物学 Q3 CELL BIOLOGY Histology and histopathology Pub Date : 2024-11-01 Epub Date: 2024-03-06 DOI:10.14670/HH-18-730
Shreya Das, B Preethi, Sapana Kushwaha, Richa Shrivastava
{"title":"Therapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management.","authors":"Shreya Das, B Preethi, Sapana Kushwaha, Richa Shrivastava","doi":"10.14670/HH-18-730","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcopenia is a progressive and generalized loss of skeletal muscle and functions associated with ageing with currently no definitive treatment. Alterations in gut microbial composition have emerged as a significant contributor to the pathophysiology of multiple diseases. Recently, its association with muscle health has pointed to its potential role in mediating sarcopenia. The current review focuses on the association of gut microbiota and mediators of muscle health, connecting the dots between the influence of gut microbiota and their metabolites on biomarkers of sarcopenia. It further delineates the mechanism by which the gut microbiota affects muscle health with progressing age, aiding the formulation of a multi-modal treatment plan involving nutritional supplements and pharmacological interventions along with lifestyle changes compiled in the review. Nutritional supplements containing proteins, vitamin D, omega-3 fatty acids, creatine, curcumin, kefir, and ursolic acid positively impact the gut microbiome. Dietary fibres foster a conducive environment for the growth of beneficial microbes such as <i>Bifidobacterium, Faecalibacterium, Ruminococcus, and Lactobacillus</i>. Probiotics and prebiotics act by protecting against reactive oxygen species (ROS) and inflammatory cytokines. They also increase the production of gut microbiota metabolites like short-chain fatty acids (SCFAs), which aid in improving muscle health. Foods rich in polyphenols are anti-inflammatory and have an antioxidant effect, contributing to a healthier gut. Pharmacological interventions like faecal microbiota transplantation (FMT), non-steroidal anti-inflammatory drugs (NSAIDs), ghrelin mimetics, angiotensin-converting enzyme inhibitors (ACEIs), and butyrate precursors lead to the production of anti-inflammatory fatty acids and regulate appetite, gut motility, and microbial impact on gut health. Further research is warranted to deepen our understanding of the interaction between gut microbiota and muscle health for developing therapeutic strategies for ameliorating sarcopenic muscle loss.</p>","PeriodicalId":13164,"journal":{"name":"Histology and histopathology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histology and histopathology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14670/HH-18-730","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Sarcopenia is a progressive and generalized loss of skeletal muscle and functions associated with ageing with currently no definitive treatment. Alterations in gut microbial composition have emerged as a significant contributor to the pathophysiology of multiple diseases. Recently, its association with muscle health has pointed to its potential role in mediating sarcopenia. The current review focuses on the association of gut microbiota and mediators of muscle health, connecting the dots between the influence of gut microbiota and their metabolites on biomarkers of sarcopenia. It further delineates the mechanism by which the gut microbiota affects muscle health with progressing age, aiding the formulation of a multi-modal treatment plan involving nutritional supplements and pharmacological interventions along with lifestyle changes compiled in the review. Nutritional supplements containing proteins, vitamin D, omega-3 fatty acids, creatine, curcumin, kefir, and ursolic acid positively impact the gut microbiome. Dietary fibres foster a conducive environment for the growth of beneficial microbes such as Bifidobacterium, Faecalibacterium, Ruminococcus, and Lactobacillus. Probiotics and prebiotics act by protecting against reactive oxygen species (ROS) and inflammatory cytokines. They also increase the production of gut microbiota metabolites like short-chain fatty acids (SCFAs), which aid in improving muscle health. Foods rich in polyphenols are anti-inflammatory and have an antioxidant effect, contributing to a healthier gut. Pharmacological interventions like faecal microbiota transplantation (FMT), non-steroidal anti-inflammatory drugs (NSAIDs), ghrelin mimetics, angiotensin-converting enzyme inhibitors (ACEIs), and butyrate precursors lead to the production of anti-inflammatory fatty acids and regulate appetite, gut motility, and microbial impact on gut health. Further research is warranted to deepen our understanding of the interaction between gut microbiota and muscle health for developing therapeutic strategies for ameliorating sarcopenic muscle loss.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
调节肠道微生物健康的治疗策略:治疗肌肉疏松症的方法。
肌肉疏松症是一种与衰老有关的进行性、全身性骨骼肌和功能丧失,目前尚无确切的治疗方法。肠道微生物组成的改变已成为多种疾病病理生理学的重要因素。最近,肠道微生物与肌肉健康的关系表明,肠道微生物在介导肌肉疏松症方面具有潜在作用。本综述重点探讨肠道微生物群与肌肉健康介质的关联,将肠道微生物群及其代谢物对肌肉疏松症生物标志物的影响联系起来。它进一步阐明了肠道微生物群随着年龄增长影响肌肉健康的机制,有助于制定多模式治疗方案,包括营养补充剂、药物干预以及改变生活方式。含有蛋白质、维生素 D、欧米伽-3 脂肪酸、肌酸、姜黄素、酸乳酒和熊果酸的营养补充剂对肠道微生物群有积极影响。膳食纤维为双歧杆菌、粪便杆菌、反刍球菌和乳酸杆菌等有益微生物的生长创造了有利环境。益生菌和益生元能抵御活性氧(ROS)和炎症细胞因子。它们还能增加短链脂肪酸(SCFA)等肠道微生物群代谢物的产生,有助于改善肌肉健康。富含多酚的食物具有抗炎和抗氧化作用,有助于改善肠道健康。药物干预,如粪便微生物群移植(FMT)、非甾体抗炎药(NSAIDs)、胃泌素模拟物、血管紧张素转换酶抑制剂(ACEIs)和丁酸盐前体,可导致抗炎脂肪酸的产生,并调节食欲、肠道蠕动和微生物对肠道健康的影响。我们有必要开展进一步的研究,以加深对肠道微生物群与肌肉健康之间相互作用的了解,从而开发出改善肌肉疏松性肌肉损失的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Histology and histopathology
Histology and histopathology 生物-病理学
CiteScore
3.90
自引率
0.00%
发文量
232
审稿时长
2 months
期刊介绍: HISTOLOGY AND HISTOPATHOLOGY is a peer-reviewed international journal, the purpose of which is to publish original and review articles in all fields of the microscopical morphology, cell biology and tissue engineering; high quality is the overall consideration. Its format is the standard international size of 21 x 27.7 cm. One volume is published every year (more than 1,300 pages, approximately 90 original works and 40 reviews). Each volume consists of 12 numbers published monthly online. The printed version of the journal includes 4 books every year; each of them compiles 3 numbers previously published online.
期刊最新文献
Correlation of NAT10 expression with clinical data and survival profiles in esophageal squamous cell carcinoma patients, and its impact on cell proliferation and apoptosis. Qualitative evaluations of reactive microglial heterogeneity in cultured porcine retina. S100A2 upregulates GLUT1 expression to promote glycolysis in the progression of nasopharyngeal carcinoma. Oridonin alleviates inflammation and endoplasmic reticulum stress in pediatric pneumonia via regulating the SIRT1-mediated Wnt/β-catenin signaling pathway. Brain endothelial cell activation and dysfunction associate with and contribute to the development of enlarged perivascular spaces and cerebral small vessel disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1